secwatch.observer — SEC 8-K summary
======================================

Issuer:     FENNEC PHARMACEUTICALS INC. (FENC)
CIK:        0001211583
Form:       8-K
Filed at:   2023-12-06T23:59:59+00:00
Accession:  0001104659-23-123728
Event type: debt
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fennec closes $5M tranche of convertible notes with Petrichor; extends remaining $15M draw to Dec 2024
--------------------------------------------------------------------------------

- Closed third tranche of $5M senior secured convertible notes under existing SPA with Petrichor.
- Conversion price set at $7.89/share (20% premium to VWAP prior to PEDMARK FDA approval on Sep 20, 2022).
- Note matures Aug 19, 2027; interest rate = greater of US Prime or 3.5% + 4.5% margin; PIK for first 12 months.
- SPA Amendment extends draw period for remaining $15M from Dec 31, 2023 to Dec 31, 2024.
- Proceeds support global launch of PEDMARK and market expansion into adolescent/young adult population.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1211583/000110465923123728/0001104659-23-123728-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1211583/000110465923123728/tm2332198d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-123728

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer